Key Investor Signals
Human-plasma tests removed 2–3× more protein-bound toxins
University of Twente research underlying M3Nephron’s membrane technology removed two to three times more protein-bound toxins than conventional dialysis membranes in human-plasma tests.
Startupfonds backing and imec.istart.nl selection
M3Nephron secured Startupfonds Overijssel financing in August 2026 and joined imec.istart.nl. The Dutch accelerator provides €100,000 in initial pre-seed funding.
Granted US patent covers core mixed-matrix technology
US patent 11,806,676 covers simultaneous removal of endotoxins and uremic solutes. University of Twente owns the patent, with Dimitrios Stamatialis named as an inventor.
Other Positive Signals
- Founded as an official University of Twente spin-off with Novel-T support in early 2025.
- Underlying membrane research received backing from the Dutch Kidney Foundation, Health~Holland, the EU and NWO.
Team
Michel Simons
Co-founder & CEO
- Led marketing for Philips Handheld Diagnostics, supporting portfolio development for point-of-care diagnostic products.
- Worked at Baxter Healthcare and co-authored a study on the cost-effectiveness of assisted peritoneal dialysis in the Netherlands.
- Brings 25+ years across clinical diagnostics, medical devices and pharma, spanning product development, commercialization and launches.
Dimitrios Stamatialis
Co-founder & CSO
- Full professor at the University of Twente, leading the Advanced Organ Bioengineering and Therapeutics group.
- Co-inventor of M3Nephron’s mixed matrix membrane technology and named inventor on its core granted US patent.
- Has led mixed-matrix dialysis membrane research since 2008, including peer-reviewed testing in human plasma.
Product
M3Nephron is developing mixed matrix membrane dialyzers for hemodialysis. Its dual-function membrane combines filtration and adsorption to remove harder-to-clear toxins from blood while supporting dialysate regeneration and reuse.
Improves removal of hard-to-clear toxins
The membrane combines filtration and adsorption to capture protein-bound uremic toxins that conventional hemodialysis removes inefficiently, aiming to improve blood purification.
Regenerates dialysate to cut water use
The membrane is designed to remove contaminants from spent dialysate so the fluid can be regenerated and reused, reducing purified-water and dialysate requirements.
Simplifies home and portable dialysis
Lower water and dialysate requirements could reduce reliance on reverse-osmosis systems, making the technology easier to deploy in home, portable and future wearable dialysis devices.
Market Overview
Kidney failure creates a large, recurring treatment burden because patients who cannot receive a transplant depend on long-term kidney replacement therapy. Hemodialysis remains time-intensive and infrastructure-heavy, creating demand for systems that can move more treatment into the home.
M3Nephron addresses two constraints that matter for decentralised dialysis: harder-to-remove toxins and the water and dialysate infrastructure around treatment. Home dialysis is still a minority of global dialysis use, while the commercial market for home systems is projected to expand substantially.
People receiving dialysis or kidney transplantation worldwide in 2023, nearly three times the 1990 level.
In-center hemodialysis is typically performed three times a week, with sessions lasting about 3–4 hours.
Share of global dialysis patients treated at home in 2023, including hemodialysis and peritoneal dialysis.
Projected global home dialysis systems market in 2033, up from $15.6B in 2023 at an 8.5% CAGR.
Comparable Outcomes
NxStage Medical
NxStage developed medical devices for home dialysis and critical care, including systems designed to give patients more flexibility outside traditional dialysis centers. Fresenius Medical Care completed the acquisition in 2019, valuing NxStage at about $2.0B.
Outset Medical
Outset developed Tablo, a hemodialysis system designed to reduce dialysis complexity and support treatment across hospitals, clinics and the home. Outset priced its September 2020 IPO at $27 per share, implying a market cap of about $1.14B.
Interested in More Startups Like M3Nephron?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.